Abstract
In various malignancies, photodynamic therapy (PDT) is a useful laser treatment option that achieves a strong necrotic effect on tumor cells by the cytocidal effects of singlet super-oxidization following the specific accumulation of a photosensitizer in cancer cells. Based on our previous trial using Photofrin-PDT in bile duct carcinoma (BDC), drug retention of the photosensitizer for a prolonged period and the associated sun-burn like dermatitis were serious and persistent side effects of PDT. To overcome this side effect, we performed PDT in 3 case of BDC using the next generation photosensitizer, talaporfin sodium (Npe6: Laserphyrin), which is rapidly metabolized at an earlier stage in comparison with that of Photofrin. These 3 cases of BDC included 2 cases of non-resectable BDC and one case of residual cancer infiltration at the cut-end of the hepatic duct after surgery. There were no severe toxic complications, but mild photosensitivity was diagnosed in one patient. Although the safety of new PDT using Laserphyrin was confirmed in the present cases, further examination of skin photosensitivity or other side effects in a larger number of patients remains necessary. Furthermore, careful management and follow-up of treatment effects on BDC are also necessary.
